Related Experiment Video
Updated: Nov 20, 2025
Enrichment for Chemoresistant Ovarian Cancer Stem Cells from Human Cell Lines
Published on: September 10, 2014
Differential gene expression in cisplatin-resistant and -sensitive testicular germ cell tumor cell lines
Jan Roška1, Lenka Wachsmannová1, Lenka Hurbanová1
1Department of Genetics, Cancer Research Institute, Biomedical Research Center, Slovak Academy of Sciences, Bratislava, Slovak Republic.
Abstract:
Testicular germ cell tumors (TGCTs) represent a well curable malignity due to their exceptional response to cisplatin (CDDP). Despite remarkable treatment results, approximately 5% of TGCT patients develop CDDP resistance and die. Exceptional curability makes TGCTs a highly valuable model system for studying the molecular mechanisms of CDDP sensitivity. Our study was aimed at revealing difference in gene expression between the CDDP-resistant and -sensitive TGCT cell lines, and hence at identifying candidate genes that could serve as potential biomarkers of CDDP response. Using gene expression array, we identified 281 genes that are differentially expressed in CDDP-resistant compared to -sensitive TGCT cell lines. The expression of 25 genes with the highest fold change was validated by RT-qPCR. Of them, DNMT3L, GAL, IGFBP2, IGFBP7, L1TD1, NANOG, NTF3, POU5F1, SOX2, WNT6, ZFP42, ID2, PCP4, SLC40A1 and TRIB3, displayed comparable expression change in gene expression array and RT-qPCR, when all CDDP-resistant TGCT cell lines were pairwise combined with all -sensitive ones. Products of the identified genes are pluripotency factors, or are involved in processes, such as cell metabolism, proliferation or migration. We propose that, after clinical validation, these genes could serve as prognostic biomarkers for early detection of CDDP response in TGCT patients.
Insights
Testicular germ cell tumors (TGCTs) are highly curable, but some patients develop cisplatin (CDDP) resistance. This study identified key gene expression differences to find potential biomarkers for predicting CDDP response in TGCT patients.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- Testicular germ cell tumors (TGCTs) are highly curable due to excellent response to cisplatin (CDDP).
- A subset of TGCT patients (approx. 5%) develop resistance to CDDP, leading to treatment failure and mortality.
- TGCTs serve as a valuable model for studying cisplatin sensitivity mechanisms due to their curability.
Purpose of the Study:
- To identify differences in gene expression between CDDP-resistant and CDDP-sensitive TGCT cell lines.
- To discover candidate genes that could serve as potential biomarkers for predicting CDDP response in TGCT patients.
- To understand the molecular basis of CDDP resistance in TGCT.
Main Methods:
- Gene expression array analysis was performed to identify differentially expressed genes.
- Quantitative real-time PCR (RT-qPCR) was used to validate the expression of top candidate genes.
- Comparison of gene expression profiles between resistant and sensitive TGCT cell lines.
Main Results:
- Gene expression array identified 281 differentially expressed genes between CDDP-resistant and -sensitive TGCT cell lines.
- RT-qPCR validated the expression changes for 15 genes, including pluripotency factors and genes involved in cell metabolism, proliferation, and migration.
- Genes such as DNMT3L, GAL, IGFBP2, NANOG, POU5F1, SOX2, and WNT6 showed consistent differential expression.
Conclusions:
- The identified genes, including pluripotency factors and those involved in cellular processes, show promise as potential biomarkers.
- Clinical validation of these genes could enable early detection of CDDP response in TGCT patients.
- These findings contribute to understanding CDDP resistance mechanisms and improving TGCT treatment strategies.
